Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.

ABSTRACT:

Background

Mast cells are key players in innate immunity and the T_H2 adaptive immune response. The latter counterbalances the T_H1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published.

Objective

To study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting.

Methods

Clinical follow-up and outcom

SUBMITTER: Rossignol J 

PROVIDER: S-EPMC8780123 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature